{"schema_version":"secwatch.filing_event.v1","accession":"0001722482-24-000161","form_type":"8-K","ticker":"AVTR","cik":"0001722482","company_name":"Avantor, Inc.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.363369+00:00","generated_at":"2026-05-30T10:05:48.618548+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avantor Q3 net sales $1.71B (-0.3%), net income $57.8M, raises FCF guidance","bullets":["Net sales $1,714.4M, down 0.3% reported; organic decline 0.7%; currency tailwind of 0.4%.","GAAP diluted EPS $0.08; adjusted EPS $0.26; adjusted EBITDA $302.5M (17.6% margin).","Lab Solutions sales +1.1% reported (+0.6% organic); Bioscience Production -3.2% (-3.5% organic).","Operating cash flow $244.8M; free cash flow $204.0M; management raised full-year FCF guidance.","Adjusted net leverage 3.8x; bioprocessing outperformance and cost programs ahead of plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001722482-24-000161","json":"https://secwatch.observer/filing/0001722482-24-000161.json","markdown":"https://secwatch.observer/filing/0001722482-24-000161.md","text":"https://secwatch.observer/filing/0001722482-24-000161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722482/000172248224000161/0001722482-24-000161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722482/000172248224000161/avtr-20241025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:05:48.618548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}